How Common Is Loss of Taste in COVID-19
Loss of taste, also called ageusia or hypogeusia, remains a recognized symptom of COVID-19. Early pandemic data from the World Health Organization and peer-reviewed studies listed it among the top clinical features, alongside fever and cough. The U.S. Centers for Disease Control and Prevention continues to include it in its symptom guidance. Research published in journals linked by the National Institutes of Health shows that prevalence varies by variant, with some lineages causing higher rates of chemosensory dysfunction than others. For the latest global statistics, the CDC COVID Data Tracker provides updated hospitalization and symptom surveillance reports here.
During the initial waves, studies reported that up to 80 percent of symptomatic patients experienced some form of smell or taste disorder. More recent data indicate that the Omicron subvariants generally produce lower rates of complete taste loss compared with earlier strains. The JAMA Otolaryngology–Head & Neck Surgery network and other academic sources continue to publish meta-analyses that refine these estimates. According to a large-scale review hosted by the National Library of Medicine, persistent chemosensory issues affect a minority of patients even after mild acute infections here.
Why COVID-19 Causes Loss of Taste
The primary mechanism involves damage to sustentacular cells in the olfactory epithelium, which indirectly disrupts taste perception because flavor relies heavily on smell. The SARS-CoV-2 virus binds to ACE2 receptors, which are expressed in nasal and oral epithelial tissues. Research teams at institutions such as Harvard Medical School and Johns Hopkins Medicine have mapped how viral entry leads to local inflammation and temporary disruption of taste bud signaling. The NIH National Institute on Deafness and Other Communication Disorders funds ongoing studies on these pathways here.
In some cases, direct infection of taste receptor cells contributes to hypogeusia or complete ageusia. Inflammatory cytokines released during the immune response can further impair nerve signaling related to taste. The condition is usually temporary, but a subset of patients experience prolonged dysfunction lasting weeks or months. The term post-acute sequelae of SARS-CoV-2 includes persistent chemosensory symptoms, and researchers continue to investigate risk factors such as viral load, vaccination status, and baseline neurological health here.
Recovery Timeline and Treatment Options
Most patients recover their sense of taste within weeks, with studies showing significant improvement by four to six weeks after symptom onset. A minority experience symptoms for three months or longer, and a smaller group reports lasting changes beyond six months. The Global Consortium for Chemosensory Research has published standardized patient-reported outcome measures that track recovery trajectories across populations. Clinicians often recommend olfactory training, which involves repeated exposure to distinct scents to support neural recovery here.
Treatment remains primarily supportive, with no universally approved drug specifically for COVID-related taste loss. Some physicians prescribe short courses of corticosteroids or recommend supplements such as alpha-lipoic acid, though evidence is mixed. The FDA has authorized certain therapies for acute COVID-19 that may indirectly reduce the duration of symptoms by lowering viral load early in infection. Patients with persistent dysfunction can seek evaluation through otolaryngology or neurology specialists, and insurance coverage varies by plan and provider